#colby-parkinson

#colby-parkinson

When Lorraine Kelly Donnelly felt a cramp in her left hand at the start of 2025, she didn't think anything of it. But when a week later the pain was still there, she made an appointment to see her GP.

The Stanley Family Foundation announced another $280 million for the Stanley Center for Psychiatric Research at Broad Institute earlier this month, bringing its total contributions to the Massachusetts-based nonprofit over $1 billion.

The condition, called recessive RNU2-2-related neurodevelopmental disorder, is associated with seizures and severe developmental delay in children less than a year-old, in areas such as speech and walking.

MAIMONIDES HEALTH HAS OPENED THE FIRST WOMEN'S NEUROLOGY CENTER in New York City, a comprehensive-specialty neurology and OB/GYN care practice designed to meet women's unique neurologic health care needs throughout the lifespan. The first of its kind in the five boroughs, this neurology center will utilize a comprehensive care model based on emerging medical knowledge that helps women of all ages achieve long-term neurologic health.

Actor James Van Der Beek died on 11 February, aged 48; he had been diagnosed in 2023 with colorectal cancer. According to the World Health Organization, colorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths worldwide. While rates are declining overall, cases among younger people are rising. This is a curable cancer if diagnosed early, says Dr Deirdre Cohen, director of the gastrointestinal oncology program for the Mount Sinai health system and an associate professor of medicine. It's important to bring any symptoms to the attention of your physician.

Haavik was surprised to hear this because the scientific data do not suggest an unequivocal link between low levels of the neurotransmitter dopamine and ADHD. But the idea that low dopamine is a direct cause of ADHD is a common misconception, one that's amplified on social media and even in popular books about the condition. The reality, Haavik and other researchers say, is that the causes of ADHD are more diverse and nuanced than a simple deficit in one chemical cue in the brain.

Most people will forget a name, misplace their phone, or lose track of a conversation at some point. Usually, those moments pass without much thought. But for many adults, especially as they age, small lapses can trigger a much deeper fear: Is this the beginning of cognitive decline? As a neurologist, I hear this concern often. And as a researcher, I have learned something important: Worry about cognition and cognitive disease are not the same thing.

But questions remain about the accuracy and uncertainty of these tests, and experts caution that the assays aren't ready for prime time. While the results here are encouraging, they are not yet at the level of having significant clinical benefit for individual patients, says Corey Bolton, a clinical neuropsychologist and an assistant professor of medicine at Vanderbilt University Medical Center, who was not involved in the new study.

Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare genetic disorder primarily affecting boys, caused by a deficiency in the enzyme needed to break down sugar molecules. This harmful buildup in cells and tissues impacts multiple body systems, causing frequent infections, organ enlargement and developmental disabilities. Management involves supportive care and enzyme replacement therapy, as there is currently no cure,

Northwestern University has launched the Simpson Querrey Brain Health Institute (SQ-Brain), made possible by nearly $25 million in philanthropic funding from university trustee Kimberly K. Querrey ('22, '23 P). SQ-Brain envisions a future where our brains last as long as our bodies a world where brain health is continuously measurable, modifiable and monitorable across the lifespan, and where prevention of cognitive decline and brain injury is anchored in neurovascular biology and precision medicine.

New therapies for Alzheimer's disease should target a particular gene linked to the condition, according to researchers who said most cases would never arise if its harmful effects were neutralised. The call to action follows the arrival of the first wave of drugs that aim to treat Alzheimer's patients by removing toxic proteins from the brain. While the drugs slow the disease down, the benefits are minor,

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life. But, ironically, that life-saving rush of blood can also trigger a second wave of damage - killing brain cells, fueling inflammation and increasing the odds of long-term disability. Now, in a study published in the journal Neurotherapeutics, Northwestern University scientists have developed an injectable regenerative nanomaterial that helps protect the brain during this vulnerable window.

But these studies typically require large numbers of patients, huge amounts of data, and thorough follow-ups, none of which comes easy or free. The upshot is fewer investigations into scenarios that are clinically important but unlikely to yield a profit for the firms funding them. Accordingly, researchers have been developing an option that uses real-world data from insurers to save patients from falling through the cracks.